Semin Thromb Hemost 2003; 29(2): 227-234
DOI: 10.1055/s-2003-38839
Copyright © 2003 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Neonatal Thromboembolism

Ulrike Nowak-Göttl1 , Andrea Kosch1 , Nicole Schlegel2
  • 1Pediatric Hematology/Oncology, University Children's Hospital, Münster, Germany
  • 2Laboratoire D'Hématologie Biologique, Hopital Robert Debre, Paris, France
Further Information

Publication History

Publication Date:
23 April 2003 (online)

ABSTRACT

In neonates and infants numerous clinical and environmental conditions such as the use of central lines, cardiac diseases and polycythemia, renal diseases such as congenital nephrotic syndrome and neonatal hemolytic uremic syndrome, peripartal asphyxia, infants of diabetic mothers, dehydration, septicemia, necrotizing enterocolitis, acute respiratory distress syndrome, and extracorporeal membrane oxygenation lead to elevated thrombin generation and subsequent thrombus formation. Genetic prothrombotic defects [protein C, protein S and antithrombin deficiency, mutations of coagulation factor V and factor II, elevated lipoprotein (a)] have been established as risk factors for thromboembolic events. The interpretation of laboratory results relies on age-dependent normal reference values. Because appropriate clinical trials are missing in these age groups, treatment recommendations are adapted from small-scale studies in neonates and infants and from guidelines relating to adult patient protocols. Secondary long-term anticoagulation should be administered on an individual basis.

REFERENCES

  • 1 Schmidt B, Andrew M. Neonatal thrombosis: report of a prospective Canadian and international registry.  Pediatrics . 1995;  95 936-943
  • 2 Nowak-Göttl U, von Kries R, Göbel U. Neonatal symptomatic thromboembolism in Germany: two year survey.  Arch Dis Child . 1997;  76 F163-F167
  • 3 Nowak-Göttl U, Dübbers A, Kececioglu D. et al . Factor V Leiden, protein C and lipoprotein (a) in catheter related thrombosis in childhood-a prospective study.  J Pediatr . 1997;  131 608-612
  • 4 Vitiello R, McCrindle B W, Nykanen D. et al . Complications associated with pediatric cardiac catheterization.  J Am Col Cardiol . 1998;  32 1433-140
  • 5 Salonvaara M, Riikonen P, Kekomaki R. et al . Clinical symptomatic central venous catheter-related deep venous thrombosis in newborns.  Acta Paediatr . 1999;  88 642-646
  • 6 Boo N Y, Wong N C, Zulkifli S S. et al . Risk factors associated with umbilical vascular catheter-associated thrombosis in newborn infants.  J Pediatr Child Health . 1999;  35 460-465
  • 7 Schwartz D S, Gettner P A, Konstantino M M. et al . Umbilical venous catheterization and the risk of portal vein thrombosis.  J Pediatr . 1997;  131 760-762
  • 8 Sträter R, Vielhaber H, Kassenböhmer R. et al . Genetic risk factors of thrombophilia in ischaemic childhood stroke of cardiac origin. A prospective ESPED survey.  Eur J Pediatr . 1999;  158 S122-S125
  • 9 Schlegel N. Thromboembolic risks and complications in nephrotic children.  Semin Thromb Hemost . 1997;  23 271-280
  • 10 Hagstrom J N, Walter J, Bluebond-Langner R. et al . Prevalence of the factor V Leiden mutation in children and neonates with thromboembolic disease.  J Pediatr . 1998;  133 777-781
  • 11 Heller C, Schobess R, Kurnik K. et al . Abdominal venous thrombosis in neonates and infants: Role of prothrombotic risk factors-a multicentre case-control study.  Br J Haematol . 2000;  111 534-539
  • 12 Lane D A, Mannucci P M, Bauer K A. et al . Inherited thrombophilia: part 1.  Thromb Haemost . 1996;  76 651-662
  • 13 Dahlbäck B, Carlsson M, Svensson P J. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C.  Proc Natl Acad Sci USA . 1993;  90 1004-1008
  • 14 Bertina R M, Koeleman B PC, Koster T. et al . Mutation in blood coagulation factor V associated with resistance to activated protein C.  Nature . 1994;  369 64-67
  • 15 Poort S R, Rosendaal F R, Reitsma P H, Bertina R M. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis.  Blood . 1996;  88 3698-3703
  • 16 Mudd S H, Skovby F, Levy H L. et al . The natural history of homocystinuria due to cystathionine-beta-synthase deficiency.  Am J Hum Genet . 1985;  37 1-31
  • 17 Nowak-Göttl U, Junker R, Hartmeier M. et al . Increased lipoprotein (a) is an important risk factor for venous thrombosis in childhood.  Circulation . 1999;  100 743-748
  • 18 Nowak-Göttl U, Sträter R, Heinecke A. et al . Lipoprotein (a) and genetic polymorphisms of clotting factor V, prothrombin and methylenetetrahydrofolate reductase are risk factors of ischaemic stroke in childhood.  Blood . 1999;  94 3678-3682
  • 19 Ehrenforth S, Junker R, Koch H G. et al . Multicentre evaluation of combined prothrombotic defects with thrombophilia in childhood.  Eur J Pediatr . 1999;  158 S97-S104
  • 20 Junker R, Koch H G, Auberger K. et al . Prothrombin G20210A gene mutation and further prothrombotic risk factors in childhood thrombophilia.  Arterioscler Thromb Vasc Biol . 1999;  19 2568-2572
  • 21 Andrew M. Developmental hemostasis: relevance to thromboembolic complications in pediatric patients.  Thromb Haemost . 1995;  74 415-425
  • 22 Ries M, Klinge J, Rauch R. Age-related reference values for activation markers of the coagulation and fibrinolytic systems in children.  Thromb Res . 1997;  85 341-344
  • 23 Schwarz H P, Muntean W, Watzke H. et al . Low total protein S antigen but higher protein S activity due to decreased C4b-binding protein in neonates.  Blood . 1988;  71 562-565
  • 24 Cvirn G, Gallistl S, Muntean W. Effects of antithrombin and protein C on thrombin generation in newborn and adult plasma.  Thromb Res . 1999;  93 183-190
  • 25 Andrew M, Schmidt B, Mitchell L. et al . Thrombin generation in newborn plasma is critically dependent on the concentration of prothrombin.  Thromb Haemost . 1990;  63 27-30
  • 26 Ries M, Klinge J, Rauch R. et al . In vitro fibrinolysis after adding low doses of plasminogen activators and plasmin generation with and without oxidative inactivation of plasmin inhibitors in newborns and adults.  J Ped Hematol Oncol . 1996;  18 346-351
  • 27 Salafia C M, Vintzileos A M, Silberman L. et al . Placental pathology of idiopathic intrauterine growth retardation at term.  Am J Perinatol . 1992;  9 179-184
  • 28 Brenner B, Sarig G, Weiner Z. et al . Thrombophilic polymorphisms are common in women with foetal loss without apparent cause.  Thromb Haemost . 1999;  82 6-9
  • 29 Dizon-Townson D S, Meline L, Nelson L M. et al . Foetal carriers of the factor V Leiden are prone to miscarriage and placental infarction.  Am J Obstet Gynecol . 1997;  177 402-405
  • 30 Berg K, Roland B, Sande H. High Lp(a) lipoprotein level in maternal serum may interfere with placental circulation and cause foetal growth retardation.  Clin Genet . 1994;  46 52-56
  • 31 Pabinger I, Grafenhofer H, Kaider A. et al . Preeclampsia and fetal loss in women with a history of venous thromboembolism.  Arterioscler Thromb Vasc Biol . 2001;  21 874-879
  • 32 Göpel W, Kim D, Gortner L. Prothrombotic mutations as a risk factor for preterm birth.  Lancet . 1999;  353 1411-1412
  • 33 Verspyck E, Le Camp-Duchez V, Gravier A. et al . Small for gestational age infant in association with maternal prothrombin gene variant (nt 20210A).  Eur J Obstet Gynecol Reprod Biol . 1999;  83 143-144
  • 34 von Kries R, Junker R, Oberle D, Kosch A, Nowak-Göttl U. Foetal growth restriction in children with prothrombotic risk factors.  Thromb Haemost . 2001;  86 1012-1016
  • 35 Vries de S L, Eken P, Groenendaal F. et al . Antenatal onset of haemorrhagic and/or ischaemic lesions in preterm infants: prevalence and associated obstetric variables.  Arch Dis Child . 1998;  78 F51-F56
  • 36 Kraus F T, Acheen V I. Fetal thrombotic vasculopathy in the placenta: cerebral thrombi and infarcts, coagulopathies, and cerebral palsy.  Hum Pathol . 1999;  30 759-769
  • 37 Debus O, Koch H G, Kurlemann G. et al . Factor V Leiden and genetic defects of thrombophilia in childhood porencephaly.  Arch Dis Child . 1998;  78 F121-F124
  • 38 Govaets P, Matthys E, Zecic A. et al . Perinatal cortical infarction within middle cerebral artery trunks.  Arch Dis Child . 2000;  82 F59-F63
  • 39 Vielhaber H, Ehrenforth S, Koch H G. et al . Cerebral venous thrombosis in infancy and childhood: role of genetic and acquired risk factors of thrombophilia.  Eur J Pediatr . 1998;  157 555-560
  • 40 Mocan H, Beattie T J, Murphy A V. Renal venous thrombosis in infancy: long-term follow-up.  Pediatr Nephrol . 1991;  5 45-49
  • 41 Bökenkamp A, von Kries R, Nowak-Göttl U. et al . Neonatal renal venous thrombosis in Germany between 1992 and 1994; epidemiology, treatment and outcome.  Eur J Pediatr . 2000;  159 44-48
  • 42 Riikonen R S, Vahtera E M, Kekomäki R M. Physiological anticoagulants and activated protein C resistance in childhood stroke.  Acta Paediatr . 1996;  85 242-244
  • 43 Zenz W, Bodo Z, Plotho J. et al . Factor V Leiden and prothrombin gene G20210A variant in children with stroke.  Thromb Haemost . 1998;  80 763-766
  • 44 Van Beynum M I, Smeitink J A, den Heijer M. et al . Hyperhomocysteinemia: a risk for ischaemic stroke in children.  Circulation . 1999;  99 2070-2072
  • 45 Kenet G, Sadetzki S, Murad H. et al . Factor V Leiden and antiphospholipid antibodies are significant risk factors for ischaemic stroke in children.  Stroke . 2000;  31 1283-1288
  • 46 Günther G, Junker R, Sträter R. et al . Symptomatic ischaemic stroke in full-term neonates: role of acquired and genetic prothrombotic risk factors.  Stroke . 2000;  31 246-251
  • 47 Laeson S E, Butler D, Enayat M S, Williams M D. Congenital thrombophilia and thrombosis: a study in a single centre.  Arch Dis Child . 1999;  81 176-178
  • 48 Bonduel M, Hepner M, Sciuccati G. et al . Prothrombotic abnormalities in children with venous thromboembolism.  J Pediatr Hematol Oncol . 2000;  22 66-72
  • 49 Lane D A, Mannucci P M, Bauer K A. et al . Inherited thrombophilia: part 2.  Thromb Haemost . 1996;  76 824-834
  • 50 Manco-Johnson M, Abshire T, Jacobson L, Marlar R. Severe neonatal protein C deficiency: prevalence and thrombotic risk.  J Pediatr . 1991;  119 793-798
  • 51 Manco-Johnson M J, Nuss R, Key N. et al . Lupus anticoagulant and protein S deficiency in children with postvaricella purpura fulminans or thrombosis.  J Pediatr . 1996;  128 319-323
  • 52 Andrew M, Paes B, Johnston M. Development of the hemostatic system in the neonate and young infant.  Am J Pediatr Hematol Oncol . 1990;  12 95-104
  • 53 Häuseler M, Duyue D, Merz U. et al . The clinical outcome after inferior vena cava thrombosis in early infancy.  Eur J Pediatr . 1999;  158 416-420
  • 54 Andrew M, Michelson A D, Bovill E. et al . Guidelines for antithrombotic therapy in pediatric patients.  J Pediatr . 1998;  132 575-588
  • 55 Massicotte P, Adams M, Marzinotto V. et al . Low molecular weight heparin in pediatric patients with thrombotic disease: a dose finding study.  J Pediatr . 1996;  128 313-318
  • 56 Dix D, Andrew M, Marzinotto V. et al . The use of low molecular weight heparin in pediatric patients: a prospective cohort study.  J Pediatr . 2000;  136 439-445
  • 57 Kirk C R, Qureshi S A. Streptokinase in the management of arterial thrombosis in infancy.  Int J Cardiol . 1989;  25 15-20
  • 58 Nowak-Göttl U, Schwabe D, Schneider W. et al . Thrombolysis with recombinant tissue-type plasminogen activator in renal venous thrombosis in infancy.  Lancet . 1992;  340 1005
  • 59 Wever M L, Liem K D, Geven W B, Tanke R B. Urokinase therapy in neonates with catheter related central venous thrombosis.  Thromb Haemost . 1995;  73 180-185
  • 60 Farnoux C, Camard O, Pinquier D. et al . Recombinant tissue-type plasminogen activator therapy of thrombosis in 16 neonates.  J Pediatr . 1998;  133 137-140
  • 61 Weiner G M, Castle V P, DiPietro M A, Faix R G. Successful treatment of neonatal arterial thrombosis with recombinant tissue plasminogen activator.  J Pediatr . 1998;  133 133-136
  • 62 Nowak-Göttl U, Auberger K, Halimeh S. et al . Thrombolysis in newborns and infants.  Thromb Haemost . 1999;  82 S112-S116
  • 63 Manco-Johnson M J, Nuss R, Krupski W. et al . Combined thrombolytic and anticoagulant therapy for venous thrombosis in children.  J Pediatr . 2000;  136 446-453
  • 64 Marlar R A, Montgomery R, Broeckmans A W. Diagnosis and treatment of homozygous protein C deficiency.  J Pediatr . 1989;  114 528-534
  • 65 Dreyfus M, Magny J F, Bridey F. et al . Treatment of homozygous protein C deficiency and neonatal purpura fulminans with purified protein C concentrate.  N Engl J Med . 1991;  325 1565-1568
  • 66 Monagle P, Adams M, Mahoney M. et al . Outcome of pediatric thromboembolic disease: a report from the Canadian childhood thrombophilia registry.  Ped Res . 2000;  47 763-766
  • 67 Nowak-Göttl U, Junker R, Kreuz W. et al . Risk of recurrent thrombosis in children with combined prothrombotic risk factors.  Blood . 2001;  97 858-862
    >